Fugal Infection in COVID-19 Patients

NCT04914013 | Unknown

• 1 other identifier: Fungi in COVID-19
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Screening early detection of invasive fungal sinusitis in COVID-19 positive patients

Conditions

Covid19

Keywords

COVID-19, invasive fungal infection

Outcome Measures

Primary Outcomes (1)

• detection of invasive fungal sinusitis after covid 19 infection.

  diagnosis of invasive fungal post COVID-19 infection

  baseline

Secondary Outcomes (1)

• Identify specific fungi that participate in IFS

  1 month

Interventions

no intervention OTHER

no intervention

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who were diagnosed with invasive fungal sinusitis, and are survivors of Covid19 infection, all cases diagnosed on the basis of the interim guidance of the World Health Organization (WHO) for diagnosis of SARS-CoV-2. Patients were recruited from:1- Otorhinolaryngology Department, Assuit university hospital. 2- Intermediate care unit of Internal Medicine department. 3-Respiratory Intensive care unite and chest department.

You may qualify if:

• Patients who were diagnosed with invasive fungal sinusitis, and are survivors of Covid19 infection, all cases diagnosed on the basis of the interim guidance of the World Health Organization (WHO) for diagnosis of SARS-CoV-2.

You may not qualify if:

• \- Patients who received antifungal therapy within three days prior to sample collection.
• Patients refused to participate in the study.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (3)

• Fekkar A, Lampros A, Mayaux J, Poignon C, Demeret S, Constantin JM, Marcelin AG, Monsel A, Luyt CE, Blaize M. Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. Am J Respir Crit Care Med. 2021 Feb 1;203(3):307-317. doi: 10.1164/rccm.202009-3400OC.

  PMID: 33480831 BACKGROUND

• Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021 May;135(5):442-447. doi: 10.1017/S0022215121000992. Epub 2021 Apr 8.

  PMID: 33827722 BACKGROUND

• Alanio A, Delliere S, Fodil S, Bretagne S, Megarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020 Jun;8(6):e48-e49. doi: 10.1016/S2213-2600(20)30237-X. Epub 2020 May 20. No abstract available.

  PMID: 32445626 BACKGROUND

MeSH Terms

Conditions

COVID-19; Invasive Fungal Infections

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Mycoses; Bacterial Infections and Mycoses

Central Study Contacts

Maiada Hashem

CONTACT

01006559662; maiada.hashem@aun.edu.eg

Aliae Mohamed-Hussien

CONTACT

01222302352; aliaehussein@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer

Study Record Dates

• First Submitted: June 2, 2021
• First Posted: June 4, 2021
• Study Start: June 1, 2021
• Primary Completion: August 1, 2021
• Study Completion: September 1, 2021
• Last Updated: June 4, 2021

Record last verified: 2021-06